Does a cholesterol drug help prevent heart problems in people with diabetes who haven’t had heart disease yet?
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors wanted to see if adding a drug called evolocumab to regular cholesterol medicine helps protect people with diabetes from having their first heart attack, stroke, or other heart problem when they don’t already have heart disease.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 555 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors wanted to see if adding a drug called evolocumab to regular cholesterol medicine helps protect people with diabetes from having their first heart attack, stroke, or other heart problem when they don’t already have heart disease.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 555 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Authors
Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS, VESALIUS-CV Investigators
Related Content
Claims (5)
Taking a drug called evolocumab can lower the chance of having a first major heart problem by 25% in people at high risk who’ve never had a heart attack or stroke before.
For people with diabetes who are at high heart risk but don’t yet have serious artery disease, adding a drug called evolocumab to their cholesterol medicine (statin) cuts their chance of having a first heart attack, stroke, or heart-related death by about a third over nearly 5 years.
For people with diabetes who don’t have serious artery disease, adding a drug called evolocumab to their usual cholesterol medicine lowers bad cholesterol a lot — down to 52, compared to 111 without it — after a year.
For people with diabetes who are at high heart risk but don’t yet have major artery blockages, adding a drug called evolocumab to their usual cholesterol medicine cuts their chance of heart attack, stroke, or heart-related death by about a third over nearly 5 years.
For people with diabetes but no major heart artery disease, adding a drug called evolocumab to their cholesterol medicine might lower their chance of dying over five years — 7.8% of those on the drug died, compared to 10.1% on a placebo.